CSL ended its proposed $3.1bn acquisition of Talecris Biotherapeutics after the deal was blocked by the US Federal Trade Commission and said it will use some of the cash to buy back its shares, reports Bloomberg.  CSL, the world’s second-largest maker of blood plasma products, said it will repurchase as much as 9% of its stock for about A$1.6bn ($1.3bn). CSL will pay Talecris a $75m break fee after agreeing to terminate the proposal.

This entry was posted by Gwen Robinson on Tuesday, June 9th, 2009 at 4:29 and is filed under Capital markets, M&A, Private equity. Tagged with CSL, Talecris Biotherapeutics. Edit this entry.